FDA to Hold Public Hearing on Online Drug Promotion - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

FDA to Hold Public Hearing on Online Drug Promotion


ePT--the Electronic Newsletter of Pharmaceutical Technology

The US Food and Drug Administration plans to hold a public hearing to discuss the promotion of agency-regulated drugs and medical devices on the Internet and using social media tools, according to a notice in the Sept. 21, 2009, Federal Register. The meeting is a collaboration among FDA’s Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), Center for Veterinary Medicine (CVM), and the Center for Devices and Radiological Health (CDRH). The meeting is scheduled for Nov. 12–13, 2009 in Washington, DC.
 
“The continually evolving nature of the Internet, including Web 2.0 and social media tools, as well as their expansion to applications such as mobile technology, have raised questions and concerns over how to apply existing regulations to promotion in these newer media,” states the notice. “ FDA is evaluating how the statutory provisions, regulations, and policies concerning advertising and promotional labeling should be applied to product-related information on the Internet and newer technologies. Although the agency believes that many issues can be addressed through existing FDA regulations, special characteristics of Web 2.0 and other emerging technologies may require the agency to provide additional guidance to the industry on how the regulations should be applied.”
 
FDA invites public participation, as well as written comments, on this issue to help in the decision-making process for policies that regulate online and social media promotions. 
 
The agency held a similar public meeting in 1996 when the Internet was becoming popular. Since that time, blogs, microblogs, podcasts, online communities, video-sharing, Wikis, and more have emerged. Specific topics at the meeting will address, among other things:

  1. For what online communications are manufacturers, packers, or distributors
    accountable?
  2. How can manufacturers, packers, or distributors fulfill regulatory
    requirements?
  3. What parameters should apply to the posting of corrective information on Web sites controlled by third parties?
  4. When is the use of links appropriate?
  5. And questions specific to Internet adverse-event reporting.

Comments for the meeting can be submitted by Oct. 9, 2009, and after the meeting until Feb. 28, 2010, to www.regulations.gov. Registration information to attend the meeting is included in the full Federal Register notice.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What is the single greatest threat to maintaining manufacturing processes at your facility?
Quality issues
Facility/environment problems
Process development problems
Production equipment downtime
Raw material supply problems
Regulatory restrictions
Business decisions to limit production
Quality issues
75%
Facility/environment problems
0%
Process development problems
0%
Production equipment downtime
0%
Raw material supply problems
25%
Regulatory restrictions
0%
Business decisions to limit production
0%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Patent Settlements Become More Risky
Praise and Perils for Biotechnology Patent Policy
Risk-Mitigation Strategies in Drug Manufacturing for Emerging Markets
Quality Focus: Ensuring Raw Material Transparency
Advertising of Prescription Drugs  Keeping it Honest and Balanced
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here